Home › Funds › Affinity Asset Advisors, LLC › CLDX

Affinity Asset Advisors, LLC position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

Affinity Asset Advisors, LLC reported holding 1,160,499 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$37.6M, representing 1.75% of its reported portfolio and ranking #16 among its reported holdings. Affinity Asset Advisors, LLC has disclosed CLDX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.16M sh
Reported value held$37.61M
Portfolio Weight1.75%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's CLDX position evolved

Affinity Asset Advisors, LLC first disclosed a stake in CLDX in Q3 2023 at 150,000 shares (US$4.1M). The position peaked in Q3 2026 at 1,160,499 shares, worth US$37.6M. Across 11 filings, Affinity Asset Advisors, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,160,499 shares valued at US$37.6M — an increase of 460,499 shares quarter over quarter.. Notable position changes include a 167% increase in Q4 2023 (shares rose 6% over the following quarter), a 74% trim in Q3 2024 (shares fell 26% over the following quarter), a 92% trim in Q4 2024 (shares fell 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 150.00K $4.13M New
Q4 2023 400.00K $15.86M Add
Q1 2024 510.00K $21.40M Add
Q2 2024 475.40K $17.59M Reduce
Q3 2024 125.00K $4.25M Reduce
Q4 2024 9.99K $252.50K Reduce
Q3 2025 300.00K $7.76M New
Q4 2025 350.00K $9.51M Add
Q1 2026 500.00K $15.86M Add
Q2 2026 700.00K $26.05M Add
Q3 2026 1.16M $37.61M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 40 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held CLDX?

Affinity Asset Advisors, LLC has disclosed CLDX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in CLDX?

As of Q3 2026, Affinity Asset Advisors, LLC holds 1.16M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $37.61M, representing 1.75% of its reported portfolio and ranking #16.

Has Affinity Asset Advisors, LLC been buying or selling CLDX?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC increased its position in CLDX. The position peaked in Q3 2026 at 1.16M shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.